Sonic Healthcare (ASX:SHL) Still Compounding, Integration Is the Near Term Drag

The Quality Compounder, With a Margin Reset Under the Hood

Sonic Healthcare is one of the ASX 200’s higher quality compounders, and its half year result shows the earnings base is still expanding, even if margin and mix are doing some heavy lifting behind the scenes.

Here is a quick snapshot of the standout metrics:

EBITDA of A$907m, up 10% year on year (1H FY25 A$827m)
Net profit of A$262m, up 11% year on year (1H FY25 A$237m)
EPS of 53.1 cents, up 8% year on year (1H FY25 49.2 cents)
Operating cash flow of A$682m, up 10% year on year (1H FY25 A$620m)

Sonic is still growing earnings, but the gap between revenue growth (17%) and EBITDA growth (10%) is telling.

It suggests margin and mix effects are doing real work in the background, especially in the US and in lower margin acquired operations that are still early in the integration curve. In other words, the top line is growing faster than the profit line, which usually means either profitability is being diluted by mix, costs are rising faster in certain regions, or acquired businesses are coming in with lower margins that should improve over time as synergies flow through.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

A Re Rating Case, If Synergies Start to Land

Management attributed the uplift in earnings to a mix of strong reported growth plus organic growth of 5%. The result was solid, but the margin bridge is where the real story sits.

Reported EBITDA margin came in at 16.7% in 1H FY26 versus 17.7% in 1H FY25. That is a 100 bps contraction, and management was clear on what drove it.

The main drags on reported margin were:

Higher acquisition costs, rising to A$8m versus A$2m.

Germany mix and pricing pressure, with the KV quota change reducing fees, alongside mix effects.

Lower initial margins from LADR, which management framed as expected early in the integration cycle.

The UK Hertfordshire and West Essex NHS outsource contract, which remains margin dilutive and was again positioned as an expected early phase outcome.

On the balance sheet, net debt moved higher, largely acquisition driven.

Net Debt Up, But Balance Sheet Remains Controlled

Net interest bearing debt increased to A$3.6b versus A$2.818b at 30 June 2025. Management highlighted that leverage remains manageable, with debt cover at 2.5x, gearing at 29.0%, and interest cover at 9.5x. They also flagged around A$1b of headroom before the interim dividend.

The interim dividend was A$0.45 per share, 60% franked.

Capital management is also becoming a more active part of the narrative. Sonic is progressing a property monetisation option, with a sale and leaseback process underway for a Brisbane hub lab. Management indicated estimated proceeds of A$450m to A$500m, targeting completion by June 2026, and they noted the potential for a significant gain on sale.

Importantly, they also floated that proceeds could be used to fund an on market share buyback, which is the type of capital allocation lever the market tends to like, especially if the share price is not reflecting the underlying earnings durability.